New cell therapy targets hard-to-treat blood disorders

This early-stage study tests a new treatment called RN1201 for people with certain blood disorders caused by the immune system attacking the body's own cells. The treatment involves giving patients specially designed immune cells after a short course of chemotherapy to weaken the existing immune system. The goal is to see if RN1201 is safe and can help raise platelet counts and reduce bleeding in patients who have not responded to standard therapies.